高雄醫學大學圖書館 |

Metabolic drug interactions /

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Metabolic drug interactions // Rene H. Levy ... [et al.].
Published:	Philadelphia :Lippincott Williams & Wilkins, : 2000.,
Description:	xxi, 793 p. :ill. ; : 29 cm.;
Subject:	Drugs - Metabolism. -
ISBN:	0781714419 (alk. paper)

Metabolic drug interactions /
Metabolic drug interactions /Rene H. Levy ... [et al.]. - Philadelphia :Lippincott Williams & Wilkins,2000. - xxi, 793 p. :ill. ;29 cm.

Includes bibliographical references and indexes.

Sect. I. Prediction of drug interactions from In Vitro studies: basic principles -- Ch. 1. Metabolically-based drug-drug interactions: principles and mechanisms -- Ch. 2. From In Vitro to In Vivo: an academic perspective -- Ch. 3. Industrial viewpoint: application of In Vitro drug metabolism in various phases of drug development -- Ch. 4.Regulatory viewpoint: prediction of drug interactions fromIn Vitro studies -- Sect. II. Enzymes and transporters -- Ch. 5. Cytochromes P450: historical overview -- Ch. 6. CYP1A -- Ch. 7. CYP2C -- Ch. 8. CYP2D6 -- Ch. 9. CYP2E1 --Ch. 10. CYP3A

ISBN: 0781714419 (alk. paper)Subjects--Topical Terms:

191029
Drugs
--Metabolism.

National Library of Medicine Call No.: QV 38 / M5873 2000

Metabolic drug interactions /
LDR:03213nam 22001931 4500 001 267466
008 13111916s2000 paua b 001 0 eng
020 $a 0781714419 (alk. paper)
035 $a US MARC 545
040 $a KMHK
060 1 0 $a QV 38 $b M5873 2000
245 0 0 $a Metabolic drug interactions / $c Rene H. Levy ... [et al.].
260 $a Philadelphia : $c 2000. $b Lippincott Williams & Wilkins,
300 $a xxi, 793 p. : $b ill. ; $c 29 cm.
504 $a Includes bibliographical references and indexes.
505 0 $a Sect. I. Prediction of drug interactions from In Vitro studies: basic principles -- Ch. 1. Metabolically-based drug-drug interactions: principles and mechanisms -- Ch. 2. From In Vitro to In Vivo: an academic perspective -- Ch. 3. Industrial viewpoint: application of In Vitro drug metabolism in various phases of drug development -- Ch. 4.Regulatory viewpoint: prediction of drug interactions fromIn Vitro studies -- Sect. II. Enzymes and transporters -- Ch. 5. Cytochromes P450: historical overview -- Ch. 6. CYP1A -- Ch. 7. CYP2C -- Ch. 8. CYP2D6 -- Ch. 9. CYP2E1 --Ch. 10. CYP3A
505 0 $a Ch. 11. P-glycoprotein -- Ch. 12. Other CYP: 2A6, 2B6, 4A-- Ch. 13. UDP-glucuronosyltransferases -- Ch. 14. Glutathione S-tranferases -- Ch. 15. Sulfotransferases andmethyltransferases -- Ch. 16. Epoxide hydrolases -- Sect. III. Drugs as substrates of metabolic enzymes treatment ofCNS diseases -- Ch. 17. Anticonvulsants -- Ch. 18. Antidepressants -- Ch. 19. Antipsychotics -- Ch. 20. Sedative-hypnotic and anxiolytic agents -- Ch. 21. Volatile, Intravenous, and local anesthetics -- Ch. 22. Opioid analgesics
505 0 $a Ch. 23. Agents for the treatment of migraine, Parkinson's,and Alzheimer's diseases -- Ch. 24. Calcium channel blockers -- Ch. 25. gb s-adrenoreceptor antagonists -- Ch. 26. Angiotensin II antagonists, ACE inhibitors, and diuretics -- Ch. 27. Cholesterol-lowering agents and cardiac glycosides -- Ch. 28. Antiarrhythmics -- Ch. 29. Oral anticoagulants -- Ch. 30. Oral antifungals -- Ch. 31.Antivirals -- Ch. 32. H?receptor antagonists -- Ch. 33. Analgesics-antipyretics -- Ch. 34. Nonsteroidal antiinflammatory drugs -- Ch. 35. Methylxanthines
505 0 $a Ch. 36. H?antagonists, proton-pump inhibitors, and antiemetics -- Ch. 37. Immunosuppressive agents -- Ch. 38.Estrogens and progestins -- Ch. 39. Hypoglycemic agents --Ch. 40. Antineoplastic agents -- Sect. IV. Drugs as inhibitors of metabolic enzymes treatment of CNS diseases -- Ch. 41. Anticonvulsants -- Ch. 42. Antidepressants -- Ch. 43. Neuroleptics and antipsycholtics -- Ch. 44. Calcium channel blockers -- Ch. 45. Antiarrythmics -- Ch. 46. Antimicrobials and antiparasitics -- Ch. 47. Antifungals -- Ch. 48. Protease inhibitors -- Ch. 49. H?receptor antagonists
505 0 $a Ch. 50. Inhibitors in the diet: grapefruit juice-drug interactions -- Sect. V. Drugs as inducers of metabolic enzymes -- Ch. 51. Phenobarbital, phenytoin, and carbamazepine -- Ch. 52. Rifampin, dexamethasone, and omeprazole -- Ch. 53. Isoniazid and ethanol -- Sect. VI.: Clinical Considerations -- Ch. 54. Clinical and pharmacoeconomic significance of metabolic drug interactions -- Ch. 55. Pharmacist management of drug interactions -- Ch. 56. Interactions in the elderly -- Sect. VII. Appendix.
650 0 $2 96060 $a Drugs $x Metabolism. $3 191029
650 0 $2 96060 $a Drug interactions. $3 196061
650 1 2 $2 96060 $a Drug Interactions. $3 195036
650 2 2 $a Metabolism $x drug effects. $3 349487